Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened

Key Points

• Shares fell 8% to about $6.97 on Friday, with ~1.02 million shares traded—roughly 25% below the stock's average daily volume after closing at $7.58.
• Analyst views are mixed: the consensus rating is "Hold" with an average target of $10, while Piper Sandler and Wedbush raised targets to $14 and $19 respectively and Weiss Ratings reiterated a sell.
• Company fundamentals show a market cap of about $586M and negative profitability; Replimune reported EPS of -$0.77 last quarter (beating estimates) and institutional investors own roughly 92.5% of the shares.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price dropped 8% on Friday . The company traded as low as $6.96 and last traded at $6.9730. Approximately 1,024,169 shares were traded during trading, a decline of 25% from the average daily volume of 1,369,877 shares. The stock had previously closed at $7.58.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Replimune Group in a report on Monday, December 29th. Piper Sandler raised their target price on shares of Replimune Group from $13.00 to $14.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Finally, Wedbush boosted their price target on shares of Replimune Group from $18.00 to $19.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 4th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $10.00.

Replimune Group Price Performance

The company has a 50-day simple moving average of $7.76 and a 200-day simple moving average of $7.64. The stock has a market cap of $586.25 million, a PE ratio of -2.06 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.08. Sell-side analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

Several institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC purchased a new position in Replimune Group in the 4th quarter valued at approximately $29,000. Russell Investments Group Ltd. boosted its position in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock worth $33,000 after buying an additional 7,569 shares in the last quarter. CWM LLC grew its stake in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company's stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company's stock valued at $58,000 after acquiring an additional 6,873 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Replimune Group during the 2nd quarter valued at about $69,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.